PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
01/24/12
PDL BioPharma Announces 2012 Regular Quarterly Dividends
01/05/12
PDL BioPharma Announces Settlement and Final Results of its Exchange Offer
01/05/12
PDL BioPharma to Present at the 30th Annual JP Morgan Healthcare Conference
01/03/12
PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer

